HRL Holdings Limited Overview
HRL Holdings was a Brisbane-headquartered micro-cap that converted itself from a failed geothermal explorer (Hot Rock Limited) into a specialist testing, inspection and data-management group serving Australia and New Zealand. Its rebuild started with the 2014 purchase of Octief, a Queensland asbestos and hazardous-materials consultancy. It continued with the 2014–15 purchase of Precise Consulting, a New Zealand hazardous-materials testing laboratory. The decisive step was the November 2017 acquisition of Analytica Laboratories in Hamilton, New Zealand. Analytica was a niche chemistry laboratory with leading positions in mānuka honey authentication and dairy/raw-milk testing, and it roughly doubled group revenue. Around this core, HRL built a hazmat consulting arm, a Queensland geotechnical testing unit and the Octfolio cloud software platform. By FY2021 revenue was A$34.6m and underlying EBITDA was A$7.7m. HRL's niche laboratory franchise attracted ALS Limited, which bought it in 2022 for about A$82m to deepen its ANZ food and environmental testing footprint.
What the company did
HRL Holdings was a diversified environmental and laboratory services provider operating offices and laboratories across Australia and New Zealand. ALS's acquisition announcement (6 September 2022) described HRL as a provider of sampling, laboratory testing and data-management capabilities for the food, environmental and occupational hygiene industries. McCullough Robertson, HRL's legal adviser on the takeover, summarised HRL as specialising in integrated field sampling, laboratory analysis and cloud-hosted asset management.
Third-party company profiles based on HRL's annual reports list four operating segments:
-
HAZMAT services: asbestos and hazardous-materials management, property contamination testing, workplace drug testing, environmental testing, on-site testing and monitoring.
-
Food and Environmental Laboratory services: honey testing, milk and dairy testing, food-origin testing, drugs-of-abuse laboratory testing, asbestos laboratory analysis, environmental laboratory testing, and other laboratory R&D services.
-
Geotechnical services: geotechnical investigation and study, temporary works design and inspection, construction-phase verification, earthworks supervision, soil/concrete/aggregate testing, and on-site mobile laboratory testing.
-
Software services: information-management software for asbestos and hazardous materials, field-management software, and customised workplace health and safety compliance applications (Octfolio).
The Food and Environmental Laboratory segment generated the largest share of revenue, and New Zealand was the majority geographic source of revenue (moomoo company profile, derived from HRL annual reports).
Business model and revenue model
| Revenue model component | Characterisation | Evidence |
|---|---|---|
| Fee-for-test laboratory services (per sample) | Dominant revenue model; transactional and recurring through regulatory and export-certification programmes | Analytica honey, dairy, food-origin and environmental testing |
| Consulting / field services (time-and-materials, project fees) | Hazmat surveys, asbestos management plans, air monitoring, contamination assessments | Octief (Australia), Precise Consulting (NZ) |
| Construction materials testing (project-based) | Earthworks supervision, soil/concrete/aggregate testing tied to Queensland civil construction | Geotechnical segment |
| Software (subscription / SaaS licensing) | Cloud-hosted asbestos registers and hazmat data platform | Octfolio |
| Product sales / licensing of IP | Not a material disclosed revenue line | — |
The exact revenue mix split between service, consulting and subscription revenue was not publicly disclosed beyond segment level.
Value-chain position
HRL sat in the testing, inspection and certification (TIC) value chain as an independent third-party laboratory and field-sampling provider. Its "integrated" model, which it marketed throughout its listed life, combined three steps: field sampling by consultants (Octief/Precise), laboratory analysis (Analytica and in-house asbestos laboratories), and data delivery through a cloud platform (Octfolio). The aim was to capture more of each client's compliance spend than a pure laboratory or pure consultancy could.
Customer types and end-markets
| End-market | Customer types | Key services |
|---|---|---|
| Food and agri-exports (NZ) | Honey producers and exporters, dairy processors, raw-milk suppliers, infant-formula exporters | Mānuka honey authentication, glyphosate and AFB (American foulbrood) testing, raw milk testing, export certification support via CAIQTest Pacific |
| Occupational hygiene / built environment | Building owners, government asset owners, property managers, construction contractors | Asbestos surveys, air monitoring, hazardous materials registers |
| Residential property (NZ) | Landlords, housing agencies, property managers | Methamphetamine residue testing (a material line until the 2018 market collapse) |
| Civil construction (QLD) | Contractors, engineering firms, infrastructure owners | Geotechnical testing, earthworks supervision, materials testing |
| Environmental | Councils, consultancies, industrial clients | Water testing (expanded via Water Testing Hawke's Bay), soil contamination |
Company's own description vs independent characterisation
Company/acquirer description (paraphrased from the ALS release, Sep 2022): an industry-leading provider of sampling, testing and data management for food, environmental and occupational hygiene markets, with Analytica described as an industry leader in honey and dairy testing and Octfolio as a fully integrated asbestos testing and data platform.
Independent characterisation: HRL was a sub-scale roll-up with one genuinely advantaged asset. Analytica's specialist chemistry franchise in NZ honey and dairy produced the bulk of group earnings: Taylor Collison estimated core lab testing at about 80% of group earnings in 1H FY21, with 28% EBITDA margins. Around it sat lower-margin, more cyclical consulting and construction-testing units. The hazmat arm was profitable but competitive. Geotechnical was a persistent laggard. Octfolio was strategically interesting but small. The equity story therefore came down to Analytica's growth runway versus the drag from the rest. That structure explains why a strategic buyer (ALS) could pay a 95% premium and still acquire the business at a modest multiple of group EBITDA.
Strategy
HRL's stated strategy (listed era, paraphrased from investor materials and management commentary)
-
Niche chemical testing: target specialist, defensible testing niches rather than commodity volume testing. CEO Dabelstein framed Analytica as consistent with a strategy of targeting niche chemical testing (2017).
-
Integrated sampling–lab–data model: link field consultants, laboratories and the Octfolio platform to capture the full compliance workflow.
-
Transfer Analytica capability to Australia: management said it saw the opportunity to bring Analytica's testing capability from New Zealand to Australia.
-
Acquisitive growth: pursue value-accretive acquisitions, including entry into NSW and Victoria (2018 investor presentation, via Strawman), "bolt-on" testing lines such as Water Testing Hawke's Bay (2021), and potentially a larger transformational deal (NovaPort, 2021).
-
Stable, regulated markets: an emphasis on stable markets, customer intimacy and share gains (Taylor Collison summary of management positioning, 2021).
Initiatives in the final 24 months of independence (mid-2020 to mid-2022)
| Initiative | Timing | Detail |
|---|---|---|
| Honey testing line extensions | FY2020–FY2021 | Glyphosate and AFB testing to offset normalising mānuka volumes |
| Raw milk and dairy share gains | FY2020–FY2021 | Target of the broader NZ milk product testing market (about NZ$40m per Taylor Collison) |
| CAIQTest Pacific growth | FY2021 | Revenue up 36%; export certification support |
| Water Testing Hawke's Bay acquisition | 2,021 | Expanded environmental/water testing lines in NZ |
| Geotechnical baseline contracts | 2,021 | Secured baseline volume work for the laggard geotechnical arm (NovaPort) |
| Octfolio software development | Ongoing | Recognised by investors as an under-monetised opportunity |
| Capex programme | FY2022 | About A$4m guided |
Sustainability and ESG commitments and formal cost-out programmes with targets: not publicly disclosed.
Guidance history
| Period | Guidance | Outcome |
|---|---|---|
| FY2019 (Nov 2018 AGM) | A$2.2–2.5m adverse EBITDA impact from meth screening | Delivered a materially lower FY2019 |
| 1H FY2021 | EBITDA A$3.2–3.5m | A$3.535m, at top end |
| FY2022 | Capex about A$4m | Not reported (company acquired) |
Strategy after the acquisition (as part of ALS)
ALS's stated rationale was to strengthen its Life Sciences operations with complementary food and environmental capabilities. It expected regulation and safety and quality-assurance programmes to keep driving ANZ food and environmental testing demand (ALS release, 6 Sep 2022). The visible integration steps are the rebranding of Octief to ALS Environmental Risk Services and the retention of Octfolio as ALS's hazmat data platform, which together show the "sampling + lab + digital" model being absorbed into ALS.
Products & Services
Food and Environmental Laboratory Services (Analytica Laboratories, Hamilton NZ)
| Offering | Description | Target customer | Notes |
|---|---|---|---|
| Mānuka honey authentication testing | Chemical and DNA marker testing to verify mānuka honey under NZ Ministry for Primary Industries (MPI) definitions | NZ honey producers and exporters | Analytica described by ALS as an industry leader in honey testing; volumes highly seasonal (bumper FY2020 season) |
| Honey residue testing (glyphosate) | Detection of glyphosate residues in honey for export market compliance | Honey exporters | Growth line cited by Taylor Collison in FY2021 |
| AFB (American foulbrood) testing | Testing for bacterial bee disease | Beekeepers, apiary regulators | Growth line cited by Taylor Collison in FY2021 |
| Milk and dairy testing | Raw milk and dairy product compositional and quality testing | Dairy processors, raw-milk suppliers | HRL captured raw-milk share; Taylor Collison saw a broader NZ milk product testing market of about NZ$40m as an opportunity |
| Infant formula / export certification support | Testing supporting China-bound infant formula exports via CAIQTest Pacific | Infant formula exporters | Analytica part-owned CAIQTest Pacific (Stockhead, 2017) |
| Food origin testing | Isotopic/chemical testing to verify geographic origin | Food exporters, brand owners | Listed in company service profile |
| Drugs-of-abuse laboratory testing | Laboratory analysis for workplace and residential drug testing, including methamphetamine residue | Employers, property managers, housing agencies | Volumes collapsed in NZ in 2018 |
| Asbestos laboratory analysis | Identification of asbestos in bulk, soil and air samples | Hazmat consultants (internal and external) | Supports Octief/Precise field work |
| Environmental laboratory testing | Soil, water and environmental chemistry testing | Councils, consultants, industrial clients | Expanded by Water Testing Hawke's Bay (2021) |
| Laboratory R&D services | Contract method development and research | Industry clients | Pricing not publicly disclosed |
HAZMAT Services (Octief — Australia; Precise Consulting — NZ)
| Offering | Description | Target customer |
|---|---|---|
| Asbestos surveys and audits | Inspection, sampling and identification of asbestos-containing materials | Building owners, government, schools, contractors |
| Asbestos management plans and registers | Compliance documentation under Australian WHS regulations | Asset owners, facility managers |
| Air monitoring / clearance inspections | Air sampling during and after asbestos removal | Removalists, principal contractors |
| Lead, mould and silica testing | Hazardous material identification (in-house lab offers asbestos, mould and silica analysis per ALS ERS page) | Property owners, employers |
| Property contamination testing | Soil and building contamination assessments | Property developers, owners |
| Workplace drug testing | On-site testing services | Employers |
| Occupational hygiene (e.g., ear-fit testing, exposure monitoring) | Workplace exposure assessments | Industrial employers |
Geotechnical Services (Queensland)
| Offering | Description | Target customer |
|---|---|---|
| Geotechnical investigation and study | Site investigation for design | Civil engineers, developers |
| Temporary works design and inspection | Design and verification of temporary works | Construction contractors |
| Construction-phase verification | Compliance testing during construction | Principal contractors, infrastructure owners |
| Earthworks supervision | Level 1 / Level 2-type supervision of earthworks | Civil contractors |
| Soil, concrete and aggregate testing | Materials testing laboratory services | Contractors, quarries |
| On-site mobile laboratory testing | Field labs deployed to projects | Large civil projects |
Software Services (Octfolio)
| Offering | Description | Target customer | Pricing model |
|---|---|---|---|
| Octfolio asbestos and hazmat platform | Secure cloud platform for managing asbestos registers and hazardous-materials data; still marketed by ALS ERS in 2025–2026 | Large asset owners, government agencies, property portfolios | Subscription (specific pricing not publicly disclosed) |
| Field-management software | Mobile data capture for field consultants | Consultancies, internal teams | — |
| Customised WHS compliance applications | Bespoke compliance tools | Enterprise clients | — |
Launch years and version histories for individual products are not publicly disclosed.
Financial Narrative
Coverage: HRL reported annual results through FY2021 (year ended 30 June 2021) and half-year results through 1H FY2022 (six months to 31 December 2021). It was compulsorily acquired before its FY2022 annual report would normally have been released to the market (late August 2022). No standalone HRL financials have been published since; HRL's post-acquisition results are consolidated within ALS Limited and not separately disclosed.
Income statement
Sources and notes: - FY2020 and FY2021 revenue, statutory EBITDA and statutory NPAT: Market Index financials page, compiled from HRL annual reports. Revenue FY2020 A$32,806,137; FY2021 A$34,612,000. Statutory EBITDA FY2020 A$8,579,110; FY2021 A$6,696,000. NPAT FY2020 −A$2,495,031; FY2021 A$1,312,000.
-
FY2021 underlying EBITDA (A$7.7m, +11%), underlying NPAT (A$3.2m, +27.7%) and revenue growth (+5.5%): HRL FY21 results release, via Kalkine.
-
FY2018 underlying EBITDA A$5.8m (+382%): HRL FY18 results (August 2018), via Strawman and Kalkine.
-
FY2020 underlying EBITDA and NPAT are derived by back-calculating from the disclosed FY2021 growth rates (7.7 / 1.11; 3.2 / 1.277).
-
FY2019 annual figures: not publicly disclosed in accessible sources. The AGM in November 2018 guided to a A$2.2–2.5m adverse EBITDA impact from the meth-testing downturn, about 30% of earnings (Livewire).
-
Dividends: no dividend payments by HRL are recorded in accessible sources; the dividend history is treated as nil or not publicly disclosed.
Half-year data points
Sources: 1H FY2020 from Stockhead (Feb 2020); 1H FY2021 from Taylor Collison (29 Jan 2021); 1H FY2022 from Craft (half-year to 31 Dec 2021). 1H FY2019 revenue derived from the disclosed 15% growth. The 1H FY2022 "gross profit" of A$14.7m on revenue of A$18.0m reflects a data-provider definition (likely revenue less consumables), not a conventional gross margin.
Margins
Computed from the figures in 6.1. FY2020 underlying margins use the derived underlying figures. The revenue CAGR over FY2020–FY2021 is 5.5%. The Analytica acquisition is documented as having roughly doubled group revenue in FY2018.
Balance sheet
Source: FY2020 and FY2021 net debt and FY2021 undrawn facilities from HRL FY21 results via Kalkine. Total assets, debt split, equity, goodwill and working capital are not publicly disclosed in accessible sources. Simply Wall St (2022) described the balance sheet as strong while also publishing an article saying HRL used debt "extensively". These conflicting automated assessments are noted; neither is relied on.
Cash flow
Source: FY2021 operating cash flow and FY2022 capex guidance (about A$4m) from HRL FY21 results via Kalkine. Earlier data point: in the September 2017 quarter, HRL generated A$0.405m of operating cash flow on A$5.4m of quarterly sales, with cash rising from A$0.728m to A$0.925m (Stockhead).
Commentary on trends, inflections and drivers
Inflection 1: the Analytica step-change (FY2018). Before November 2017, HRL was a hazmat consultancy generating about A$5–6m of quarterly sales (A$5.4m in the September 2017 quarter) with thin cash generation. The Analytica acquisition, funded by an equity raise at 8.5c, roughly doubled revenue and lifted underlying EBITDA by 382% to A$5.8m in FY2018. Centennial Asset Management, a cornerstone investor in the raise, stated that HRL was valued at about 6x FY2018E EV/EBITDA at the raise price, against domestic and global peers on 12–15x.
Inflection 2: the methamphetamine shock (FY2019). In 2018 the NZ meth-residue testing market collapsed after the Chief Science Advisor's report concluded that prevailing contamination thresholds were overly conservative. HRL quantified the FY2019 EBITDA impact at A$2.2–2.5m, about 30% of earnings. The stock had re-rated to about 11x FY2019 EV/EBITDA before the downgrade, which made the share-price reaction severe.
Inflection 3: recovery and the honey windfall (FY2020). FY2020 benefited from an exceptional NZ honey season despite COVID-19 disruption in April 2020. The 1H FY2020 loss alone was A$2.7m despite 15% revenue growth.
Inflection 4: normalisation and peak earnings (FY2021). Honey volumes normalised, but glyphosate and AFB testing, raw milk share gains and hazmat strength lifted underlying EBITDA 11% to A$7.7m. Net debt fell to A$0.4m and operating cash flow was A$5.5m. Final Analytica earn-out payments freed cash for growth, including the small Water Testing Hawke's Bay acquisition.
Inflection 5: softening and exit (1H FY2022). Revenue grew to A$18.0m, but the half produced a statutory net loss of A$0.73m and negative EBIT. Market commentators at the time noted that HRL's numbers had gone backward before ALS's approach. The undisturbed share price of 8.2c in June 2022 was roughly the level of the 2017 raise. That set up a takeover at a 95% premium which was still modest against HRL's peak underlying EBITDA: about A$82m equity value, roughly 10.7x FY2021 underlying EBITDA before adjusting for net debt.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Operating entities / brands | Products and services | Geography |
|---|---|---|---|
HAZMAT Services | Octief Pty Ltd (Australia); Precise Consulting (NZ) | Asbestos surveys and registers, hazmat management plans, air and dust monitoring, contamination assessments, soil sampling, workplace drug testing, on-site monitoring | Australia and NZ |
Food and Environmental Laboratory Services | Analytica Laboratories (Hamilton, NZ); in-house asbestos labs; Water Testing Hawke's Bay (from 2021); equity interest in CAIQTest Pacific | Honey (mānuka authentication, glyphosate, AFB), milk and dairy, food origin, drugs-of-abuse, asbestos, environmental and water testing; lab R&D services | Predominantly NZ |
Geotechnical Services | Queensland geotechnical testing operation | Geotechnical investigation, temporary works design and inspection, construction verification, earthworks supervision, soil/concrete/aggregate testing, mobile on-site labs | Queensland, Australia |
Software Services | Octfolio | Cloud asbestos/hazmat information management, field-management software, WHS compliance applications | Australia and NZ |
Segment Metric Details
| Segment metric | Period | Value | Source |
|---|---|---|---|
Food & Laboratory segment revenue | 1H FY2020 | A$7.5m (about 46% of A$16.3m group revenue) | HRL 1H FY20 report, via Stockhead (Feb 2020) |
HAZMAT segment profit | 1H FY2020 | Just over A$1m; only profitable segment that half | HRL 1H FY20 report, via Stockhead |
Geotechnical segment | 1H FY2020 | Underperformed the prior-corresponding period; only division to go backwards | HRL 1H FY20 report, via Stockhead |
Core laboratory testing revenue growth | 1H FY2021 | +13% year on year | Taylor Collison (29 Jan 2021) |
Core laboratory EBITDA margin | 1H FY2021 | 28% | Taylor Collison |
Core laboratory share of group earnings | 1H FY2021 | About 80% | Taylor Collison |
CAIQTest (Pacific) Limited revenue growth | FY2021 | +36% vs prior year | HRL FY21 results, via Kalkine |
Revenue drivers | FY2021 | Strong growth in the food laboratory division; higher earnings from Analytica and HAZMAT | HRL FY21 results, via Kalkine |
Segment revenue (AUD Mn) | FY2019 | FY2020 | FY2021 |
Group total | — | 32.8 | 34.6 |
Income Statement and Margin Analysis (%)
| Metric | FY2018 | FY2020 | FY2021 |
|---|---|---|---|
Revenue (AUD Mn) | — | 32.81 | 34.61 |
Revenue growth YoY (%) | — | — | 5.5 |
EBITDA statutory (AUD Mn) | — | 8.58 | 6.70 |
EBITDA underlying (AUD Mn) | 5.80 | — | 7.70 |
EBITDA underlying (derived, AUD Mn) | — | 6.94 | — |
Net income statutory NPAT (AUD Mn) | — | -2.50 | 1.31 |
Net income underlying NPAT (AUD Mn) | — | — | 3.20 |
Underlying NPAT (derived, AUD Mn) | — | 2.51 | — |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%) (Half-Yearly)
| Metric | 1H FY2019 (derived) | 1H FY2020 | 1H FY2021 | 1H FY2022 |
|---|---|---|---|---|
Revenue (AUD Mn) | 14.2 | 16.3 | — | 18.0 |
Revenue growth YoY (%) | — | 15 | — | — |
EBITDA (AUD Mn) | — | — | 3.535 | — |
EBITDA guidance range (AUD Mn) | — | — | 3.2–3.5 | — |
Gross profit (AUD Mn) | — | — | — | 14.7 |
EBIT (AUD Mn) | — | — | — | -0.569 |
Net profit after tax (AUD Mn) | — | -2.7 | — | -0.729 |
Cash at period end (AUD Mn) | — | — | — | 0.852 |
Margin Analysis (%)
| Metric | FY2020 | FY2021 |
|---|---|---|
Statutory EBITDA margin (%) | 26.2 | 19.3 |
Underlying EBITDA margin (%) | 21.2 | 22.2 |
Statutory net margin (%) | -7.6 | 3.8 |
Underlying net margin (%) | 7.7 | 9.2 |
Key Financials
| Metric | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
Net debt (AUD Mn) | 1.1 | 0.4 | — |
Undrawn debt facilities (AUD Mn) | — | 7.8 | — |
Cash at 31 Dec 2021 (AUD Mn, 1H FY22) | — | — | 0.852 |
Cash Flow
| Metric | FY2021 | FY2022 |
|---|---|---|
Operating cash flow (AUD Mn) | 5.5 | — |
Capex guidance (AUD Mn) | — | 4.0 |
Financial Ratios (x) and Margin Analysis (%)
| Ratio | FY2020 | FY2021 | Comment |
|---|---|---|---|
Net debt / underlying EBITDA (x) | 0.16 | 0.05 | Computed; very low leverage |
OCF / underlying EBITDA (%) | — | 71 | Computed: 5.5 / 7.7 |
Geographic revenue (AUD Mn)
| Geographic revenue (AUD Mn) | FY2020 | FY2021 |
|---|---|---|
Total | 32.81 | 34.61 |
Segment Overview — Food and Environmental Laboratory
| Segment | New Zealand | Australia |
|---|---|---|
Food and Environmental Laboratory | Dominant (Analytica, Hamilton; Water Testing Hawke's Bay) | Minor (in-house asbestos lab capability) |
HAZMAT | Precise Consulting | Octief (Queensland-centred, including Yatala) |
Geotechnical | — | Queensland civil and construction market |
Software (Octfolio) | Some clients | Primary market |
Share Price & Returns
| Reference point | Price (AUD) | Date / source |
|---|---|---|
2017 capital raise price | 0.085 | Oct–Nov 2017 |
Taylor Collison price target | 0.18 | 29 Jan 2021 |
52-week low before the bid | 0.075 | Simply Wall St |
Undisturbed close before the NBIO | 0.082 | 27 Jun 2022 |
Offer price | 0.16 | 30 Jun 2022 |
Intraday post-recommendation | 0.165 | 30 Jun 2022 |
Last traded (approx.) | 0.16 | Aug 2022 (Craft cites 0.2 rounded) |
Return metric (to delisting, %) | 1 year | 3 years |
HRL total share price change | 33.3 | 52.4 |
Valuation Multiples
| Multiple | HRL at 16c | Peer reference |
|---|---|---|
P/E (underlying NPAT, FY21) | about 25.7x | — |
P/E (statutory NPAT, FY21) | about 62.7x | — |
EV/EBITDA (underlying, FY21) | about 10.7x | Centennial cited peers at 12–15x EV/EBITDA (2017) |
EV/Sales (FY21) | about 2.4x | — |
Analyst Ratings & Targets
| Broker | Date | Rating | Target (AUD) |
|---|---|---|---|
Taylor Collison | 29 Jan 2021 | Outperform | 0.18 |
Consensus (Market Index / FN Arena) | Jun 2022 | Strong Buy | — |
“—” = not publicly disclosed.
Capital Markets
| Item | Detail |
|---|---|
Dividend history | No dividends identified; growth reinvestment and acquisition earn-outs prioritised |
Buyback authorisations | None identified |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Debt maturity profile | Not publicly disclosed; FY21 undrawn facilities A$7.8m |
Analyst Conclusions
Guidance and consensus
There is no management guidance or consensus for HRL Holdings, because it is no longer a reporting entity. The last forward-looking disclosures were FY2022 capex of about A$4m (August 2021) and the 2021 broker view (Taylor Collison) of about A$7.4m in FY2021 EBITDA, which HRL beat on an underlying basis (A$7.7m). The relevant outlook is now ALS's commentary on ANZ food and environmental testing demand, where ALS expects regulation and quality-assurance programmes to keep driving demand.
Bull-case arguments (for the HRL assets within ALS)
-
Niche lab economics plus scale: Analytica's 28% EBITDA-margin specialist testing can grow faster inside ALS's ANZ network and client base than it could as a sub-scale independent.
-
Digital moat: Octfolio, retained and promoted by ALS, gives ALS a sticky software layer in asbestos compliance and supports cross-selling of lab and consulting work.
-
Regulatory tailwinds: food authenticity (mānuka), export certification (CAIQTest Pacific) and Australian asbestos WHS obligations are structural, compliance-driven demand sources.
Bear-case arguments
-
Demand fragility: the 2018 meth-testing collapse (−A$2.2–2.5m EBITDA, about 30% of earnings) showed that regulatory reinterpretation can erase a testing market almost overnight.
-
Seasonality and commodity exposure: honey volumes swing with harvests; FY2020's bumper season did not repeat in FY2021.
-
Sub-scale legacy units: geotechnical and hazmat consulting showed lower and more cyclical returns, and the group's statutory earnings were repeatedly loss-making (FY2020, 1H FY2022).
Catalysts and monitorables (next 12 months)
| Monitorable | Why it matters |
|---|---|
| ALS Life Sciences / Environmental segment commentary on ANZ food testing | The only remaining disclosure channel for former HRL businesses |
| NZ mānuka honey export volumes and MPI rule changes | Main driver of Analytica's test volumes |
| NZ dairy and infant formula export trends to China | Driver of CAIQTest Pacific and dairy testing |
| Australian asbestos and silica regulatory changes | Demand for ALS ERS (ex-Octief) and Octfolio |
| Further ALS brand rationalisation (Analytica, Precise) | Signals depth of integration |
| ALS portfolio actions in ANZ (acquisitions or divestments) | Could affect former HRL operations |
Analyst verdict
HRL Holdings is best understood as a completed corporate life cycle rather than a live investment case. Over eight years, management turned a failed geothermal shell (Hot Rock Limited) into a profitable ANZ testing group. It did so by assembling Octief, Precise Consulting and, decisively, Analytica Laboratories. The Analytica deal, funded at 8.5c per share in 2017, created the group's one genuinely advantaged asset: a specialist NZ chemistry laboratory with leading positions in mānuka honey and dairy testing, generating about 80% of group earnings at margins near 28%.
The listed record was uneven. The NZ methamphetamine-testing collapse in 2018 cut about 30% of expected earnings and damaged credibility. Statutory results swung between profit and loss because of non-operating items. The geotechnical arm consistently underperformed. Yet underlying performance recovered to a peak in FY2021 (revenue A$34.6m, underlying EBITDA A$7.7m, near-zero net debt). That gave ALS a clean, low-risk asset to buy when HRL's share price slid back to 8.2c in mid-2022.
The 16c cash offer, a 95% premium, valued HRL at about A$82m, or roughly 10.7x FY2021 underlying EBITDA. Long-term holders from the 2017 raise roughly doubled their money. However, the price sat at or below the 12–15x EV/EBITDA range investors had cited for listed TIC peers, so ALS arguably bought a strategic niche at a sub-scale discount. The rapid passage to compulsory acquisition (12 August 2022) suggests shareholders broadly accepted that trade-off.
For analysts today, HRL's relevance is twofold. First, it is a case study in micro-cap TIC consolidation: niche labs with strong margins attract strategic buyers when public markets underprice them. Second, its assets continue within ALS, where their performance is no longer separately visible. Monitoring them now means reading ALS's ANZ food and environmental commentary rather than any HRL-specific disclosure.
Key sources referenced: ALS Limited news release "ALS expands food and environmental testing services with the acquisition of HRL Holdings" (6 Sep 2022); McCullough Robertson client result note on the HRL takeover (2022); Market Index HRL company and financials pages (FY2020–FY2021 data; delisting record); Market Index news on the ALS bid (30 Jun 2022); Motley Fool Australia HRL announcement feed (Jun 2022); HRL ASX announcements as indexed by StockLight (28 and 30 Jun 2022); Business News HRL profile (delisting date 26 Aug 2022); Simply Wall St HRL final snapshot; Craft HRL profile (1H FY2022 data); Kalkine FY2018 and FY2021 results summaries; Stockhead (Oct 2017; Feb 2020); Livewire Markets (Centennial Asset Management, 2018; NovaPort Capital, 30 Jul 2021); Taylor Collison research note summary (29 Jan 2021); Strawman member summaries of HRL investor presentations and announcements; ALS Environmental Risk Services webpage (2025–2026); ALS/Octief recruitment listing (Apr 2025).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure | Notes |
|---|---|---|---|
Steven Dabelstein | Chief Executive Officer / Managing Director | — | Architect of the niche chemical testing strategy; described Analytica as a single-site lab offering capabilities HRL lacked (Stockhead, 2017) |
Darren Anderson | Former Chair / Director | Guided the company from its earliest days; resigned from the board in Feb 2020 for health reasons | Long-standing founding-era director |
Major Shareholders
| Holder | Stake | Date | Source |
|---|---|---|---|
Perennial (Perennial Value Management / associated funds) | Sold to ALS; together with other acquisitions, gave ALS 19.99% | Jun 2022 | Strawman summary of ALS/HRL announcement |
ALS Limited (via Australian Laboratory Services Pty Ltd) | 19.99% before the offer; 100% after compulsory acquisition | Jun–Aug 2022 | Market Index; McCullough Robertson |
Australian Ethical Investment | — | 2022 | Strawman commentary |
Centennial Asset Management | — | 2017–2018 | Livewire (Matthew Kidman) |
NovaPort Capital | — | 2021 | Livewire |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Ownership / listing | Positioning vs HRL |
|---|---|---|---|
Food and Environmental Lab (NZ) | Hill Laboratories | Private, NZ | NZ's largest independent lab; broad food, agri and environmental testing; principal NZ rival |
Food and Environmental Lab (NZ/AU) | Eurofins (Eurofins NZ / ELS / Australia) | Euronext Paris listed (ERF) | Global scale food and environmental testing; strong in dairy |
Food and Environmental Lab (NZ) | AsureQuality | NZ state-owned enterprise | Dominant in dairy and export assurance |
Food and Environmental Lab (ANZ) | ALS Limited (pre-acquisition) | ASX: ALQ | Global environmental and food lab; became the acquirer |
Food / commodities (ANZ) | SGS | SIX Swiss Exchange listed | Global TIC; food and agriculture |
Food / commodities (ANZ) | Bureau Veritas | Euronext Paris listed | Global TIC; food, environmental and construction |
Environmental lab (AU) | Envirolab Services | — | Major Australian environmental and asbestos lab |
Hazmat consulting (AU) | Greencap | — | National hazmat and asbestos consultancy; direct Octief rival |
Hazmat / OH consulting (ANZ) | WSP, Tetra Tech Coffey, and other engineering consultancies | Listed (TSX: WSP; NASDAQ: TTEK) | Large multidisciplinary consultancies with hazmat and geotechnical teams |
Geotechnical / materials testing (QLD) | Regional NATA-accredited construction materials labs | Mostly private | Fragmented local competition |
Hazmat software | Various asbestos register and EHS SaaS providers | Mostly private | Competing compliance software alternatives to Octfolio |
Peer Comparison FY2021
| Metric | HRL Holdings (FY2021) | Hill Laboratories |
|---|---|---|
Revenue | A$34.6m | Not publicly disclosed (private) |
Revenue growth | +5.5% | — |
EBITDA margin | 22.2% underlying | — |
“—” = not publicly disclosed.
Recent Developments
HRL ceased to exist as a reporting entity in August 2022. There is no HRL-specific corporate newsflow in the 18 months to October 2026.



